FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease ...Middle East

SILVER SPRING, Md., Dec. 18, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft-versus-host...

Hence then, the article about fda approves first mesenchymal stromal cell therapy to treat steroid refractory acute graft versus host disease was published today ( Thursday 19/12/2024 - 01:41 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease )

Also on site :

• China’s DeepSeek unveils latest model a year after upending global tech
• Ella Langley Is Hosting 'Dinner at the Opry' — Here's How You Can Grab a Seat
• Shoppers Say This 'Fabulous' 7-Piece Cookware Set at Costco Is the 'Best Money Can Buy'